JPWO2020092694A5 - - Google Patents

Info

Publication number

JPWO2020092694A5

JPWO2020092694A5 JP2021522019A JP2021522019A JPWO2020092694A5 JP WO2020092694 A5 JPWO2020092694 A5 JP WO2020092694A5 JP 2021522019 A JP2021522019 A JP 2021522019A JP 2021522019 A JP2021522019 A JP 2021522019A JP WO2020092694 A5 JPWO2020092694 A5 JP WO2020092694A5

Authority

JP

Japan

Prior art keywords

cells

hematopoietic stem

optionally substituted

patient

hematopoietic

Prior art date

2022-11-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 544
• 210000004027 cell Anatomy 0.000 claims description 227
• 230000003750 conditioning effect Effects 0.000 claims description 214
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 159
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 126
• 229960002092 busulfan Drugs 0.000 claims description 117
• 150000001875 compounds Chemical class 0.000 claims description 99
• 210000000130 stem cell Anatomy 0.000 claims description 99
• 229910052739 hydrogen Inorganic materials 0.000 claims description 84
• 239000001257 hydrogen Substances 0.000 claims description 82
• 238000002560 therapeutic procedure Methods 0.000 claims description 79
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 78
• 125000000217 alkyl group Chemical group 0.000 claims description 70
• 102000006395 Globulins Human genes 0.000 claims description 65
• 108010044091 Globulins Proteins 0.000 claims description 65
• 238000002054 transplantation Methods 0.000 claims description 65
• 125000001072 heteroaryl group Chemical group 0.000 claims description 64
• 238000002347 injection Methods 0.000 claims description 63
• 239000007924 injection Substances 0.000 claims description 63
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 61
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 61
• 230000001494 anti-thymocyte effect Effects 0.000 claims description 61
• 230000001363 autoimmune Effects 0.000 claims description 61
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 56
• 229960004397 cyclophosphamide Drugs 0.000 claims description 56
• 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 56
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 55
• 230000003394 haemopoietic effect Effects 0.000 claims description 54
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 53
• 241000283973 Oryctolagus cuniculus Species 0.000 claims description 52
• 206010033661 Pancytopenia Diseases 0.000 claims description 51
• 125000003107 substituted aryl group Chemical group 0.000 claims description 51
• 239000003795 chemical substances by application Substances 0.000 claims description 49
• 208000024389 cytopenia Diseases 0.000 claims description 49
• 229940123517 Aryl hydrocarbon receptor antagonist Drugs 0.000 claims description 48
• 208000035475 disorder Diseases 0.000 claims description 42
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 41
• 150000003839 salts Chemical class 0.000 claims description 39
• 210000004700 fetal blood Anatomy 0.000 claims description 38
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 37
• 229960000390 fludarabine Drugs 0.000 claims description 35
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 35
• 239000012453 solvate Substances 0.000 claims description 34
• 230000000069 prophylactic effect Effects 0.000 claims description 31
• 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 30
• 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 30
• 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 28
• 150000002431 hydrogen Chemical class 0.000 claims description 27
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 16
• 206010028980 Neoplasm Diseases 0.000 claims description 15
• 229960004866 mycophenolate mofetil Drugs 0.000 claims description 15
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 14
• 229930105110 Cyclosporin A Natural products 0.000 claims description 14
• 108010036949 Cyclosporine Proteins 0.000 claims description 14
• 208000030159 metabolic disease Diseases 0.000 claims description 14
• 201000011510 cancer Diseases 0.000 claims description 11
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 10
• 208000028226 Krabbe disease Diseases 0.000 claims description 10
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims description 9
• 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 9
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 9
• 229940044551 receptor antagonist Drugs 0.000 claims description 9
• 239000002464 receptor antagonist Substances 0.000 claims description 9
• 208000023275 Autoimmune disease Diseases 0.000 claims description 8
• 230000002490 cerebral effect Effects 0.000 claims description 8
• 239000003018 immunosuppressive agent Substances 0.000 claims description 8
• 108060003951 Immunoglobulin Proteins 0.000 claims description 7
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 7
• 102000018358 immunoglobulin Human genes 0.000 claims description 7
• 229960004641 rituximab Drugs 0.000 claims description 7
• 230000001506 immunosuppresive effect Effects 0.000 claims description 6
• 208000034737 hemoglobinopathy Diseases 0.000 claims description 5
• 238000001990 intravenous administration Methods 0.000 claims description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 3
• RTGDFNSFWBGLEC-UHFFFAOYSA-N Mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 claims description 2
• 229940107810 cellcept Drugs 0.000 claims description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 2
• 229940015758 omidubicel Drugs 0.000 claims description 2
• 229940002612 prodrug Drugs 0.000 claims description 2
• 239000000651 prodrug Substances 0.000 claims description 2
• 229940124589 immunosuppressive drug Drugs 0.000 claims 2
• 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims 1
• DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
• 208000016245 inborn errors of metabolism Diseases 0.000 claims 1
• 208000015978 inherited metabolic disease Diseases 0.000 claims 1
• -1 Gr1 Proteins 0.000 description 927
• 238000000034 method Methods 0.000 description 225
• 108090000623 proteins and genes Proteins 0.000 description 99
• 125000001424 substituent group Chemical group 0.000 description 84
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 77
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 70
• 125000005843 halogen group Chemical group 0.000 description 69
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 55
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 52
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 49
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 48
• 125000004076 pyridyl group Chemical group 0.000 description 46
• 125000001544 thienyl group Chemical group 0.000 description 45
• 230000001143 conditioned effect Effects 0.000 description 43
• 239000002243 precursor Substances 0.000 description 42
• 108091033409 CRISPR Proteins 0.000 description 40
• 102000040430 polynucleotide Human genes 0.000 description 38
• 108091033319 polynucleotide Proteins 0.000 description 38
• 239000002157 polynucleotide Substances 0.000 description 38
• 125000003545 alkoxy group Chemical group 0.000 description 36
• 201000010099 disease Diseases 0.000 description 36
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 35
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 34
• 125000004122 cyclic group Chemical group 0.000 description 34
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 34
• 241000700605 Viruses Species 0.000 description 33
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 33
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 32
• 239000000203 mixture Substances 0.000 description 32
• 108020004414 DNA Proteins 0.000 description 31
• 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 28
• 210000003719 b-lymphocyte Anatomy 0.000 description 26
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 26
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 26
• 210000001772 blood platelet Anatomy 0.000 description 25
• 125000005955 1H-indazolyl group Chemical group 0.000 description 24
• 206010022000 influenza Diseases 0.000 description 24
• 239000013598 vector Substances 0.000 description 24
• 125000004429 atom Chemical group 0.000 description 23
• 230000014509 gene expression Effects 0.000 description 21
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 20
• 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 20
• 235000018102 proteins Nutrition 0.000 description 20
• 102000004169 proteins and genes Human genes 0.000 description 20
• 229940107955 thymoglobulin Drugs 0.000 description 20
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 19
• 210000004962 mammalian cell Anatomy 0.000 description 19
• 125000000335 thiazolyl group Chemical group 0.000 description 19
• 210000003743 erythrocyte Anatomy 0.000 description 18
• 238000010362 genome editing Methods 0.000 description 18
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 18
• 125000003373 pyrazinyl group Chemical group 0.000 description 18
• 125000000714 pyrimidinyl group Chemical group 0.000 description 18
• 230000002829 reductive effect Effects 0.000 description 18
• 239000000427 antigen Substances 0.000 description 17
• 108091007433 antigens Proteins 0.000 description 17
• 102000036639 antigens Human genes 0.000 description 17
• 210000003995 blood forming stem cell Anatomy 0.000 description 17
• 125000002883 imidazolyl group Chemical group 0.000 description 17
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
• 229910052757 nitrogen Inorganic materials 0.000 description 17
• PZHIWRCQKBBTOW-UHFFFAOYSA-N 1-ethoxybutane Chemical compound CCCCOCC PZHIWRCQKBBTOW-UHFFFAOYSA-N 0.000 description 16
• 238000010354 CRISPR gene editing Methods 0.000 description 16
• 125000000753 cycloalkyl group Chemical group 0.000 description 16
• 125000002541 furyl group Chemical group 0.000 description 16
• 230000035755 proliferation Effects 0.000 description 16
• 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 15
• 210000001744 T-lymphocyte Anatomy 0.000 description 15
• 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 15
• 229910052799 carbon Inorganic materials 0.000 description 15
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 15
• 239000000126 substance Substances 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 14
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 14
• 229940100198 alkylating agent Drugs 0.000 description 14
• 239000002168 alkylating agent Substances 0.000 description 14
• 230000027455 binding Effects 0.000 description 14
• 230000022131 cell cycle Effects 0.000 description 14
• 108020005004 Guide RNA Proteins 0.000 description 13
• 230000006801 homologous recombination Effects 0.000 description 13
• 238000002744 homologous recombination Methods 0.000 description 13
• 239000003623 enhancer Substances 0.000 description 12
• 125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 description 12
• 210000000822 natural killer cell Anatomy 0.000 description 12
• 210000000440 neutrophil Anatomy 0.000 description 12
• 210000005259 peripheral blood Anatomy 0.000 description 12
• 239000011886 peripheral blood Substances 0.000 description 12
• 230000035897 transcription Effects 0.000 description 12
• 238000013518 transcription Methods 0.000 description 12
• 235000001014 amino acid Nutrition 0.000 description 11
• 230000005782 double-strand break Effects 0.000 description 11
• 125000005647 linker group Chemical group 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 102000039446 nucleic acids Human genes 0.000 description 11
• 108020004707 nucleic acids Proteins 0.000 description 11
• 150000007523 nucleic acids Chemical class 0.000 description 11
• 208000011580 syndromic disease Diseases 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 206010068051 Chimerism Diseases 0.000 description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 description 10
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
• 150000001413 amino acids Chemical group 0.000 description 10
• 125000003118 aryl group Chemical group 0.000 description 10
• 210000001185 bone marrow Anatomy 0.000 description 10
• 125000004432 carbon atom Chemical group C* 0.000 description 10
• 229960001265 ciclosporin Drugs 0.000 description 10
• 210000003714 granulocyte Anatomy 0.000 description 10
• 230000037361 pathway Effects 0.000 description 10
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 9
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 9
• 229940024606 amino acid Drugs 0.000 description 9
• 210000004443 dendritic cell Anatomy 0.000 description 9
• 230000000694 effects Effects 0.000 description 9
• 208000014951 hematologic disease Diseases 0.000 description 9
• 125000005842 heteroatom Chemical group 0.000 description 9
• 210000002540 macrophage Anatomy 0.000 description 9
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 8
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 8
• 102000004127 Cytokines Human genes 0.000 description 8
• 108090000695 Cytokines Proteins 0.000 description 8
• AMNPXXIGUOKIPP-UHFFFAOYSA-N [4-(carbamothioylamino)phenyl]thiourea Chemical compound NC(=S)NC1=CC=C(NC(N)=S)C=C1 AMNPXXIGUOKIPP-UHFFFAOYSA-N 0.000 description 8
• 125000003342 alkenyl group Chemical group 0.000 description 8
• 125000004419 alkynylene group Chemical group 0.000 description 8
• 210000000170 cell membrane Anatomy 0.000 description 8
• 125000001309 chloro group Chemical group Cl* 0.000 description 8
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 8
• 125000001153 fluoro group Chemical group F* 0.000 description 8
• 208000018706 hematopoietic system disease Diseases 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 8
• 102000004196 processed proteins & peptides Human genes 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 8
• 238000011282 treatment Methods 0.000 description 8
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
• 108700028369 Alleles Proteins 0.000 description 7
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 7
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 239000000556 agonist Substances 0.000 description 7
• 125000000304 alkynyl group Chemical group 0.000 description 7
• 230000000295 complement effect Effects 0.000 description 7
• 210000003979 eosinophil Anatomy 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
• 125000004433 nitrogen atom Chemical group N* 0.000 description 7
• 230000036961 partial effect Effects 0.000 description 7
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
• 206010039491 Sarcoma Diseases 0.000 description 6
• 102100034195 Thrombopoietin Human genes 0.000 description 6
• 101710113649 Thyroid peroxidase Proteins 0.000 description 6
• 125000004450 alkenylene group Chemical group 0.000 description 6
• 125000002947 alkylene group Chemical group 0.000 description 6
• 230000000735 allogeneic effect Effects 0.000 description 6
• 208000007502 anemia Diseases 0.000 description 6
• 210000000612 antigen-presenting cell Anatomy 0.000 description 6
• 210000000601 blood cell Anatomy 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 201000001981 dermatomyositis Diseases 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 238000012239 gene modification Methods 0.000 description 6
• 102000054766 genetic haplotypes Human genes 0.000 description 6
• 230000005017 genetic modification Effects 0.000 description 6
• 235000013617 genetically modified food Nutrition 0.000 description 6
• 239000003102 growth factor Substances 0.000 description 6
• 230000011132 hemopoiesis Effects 0.000 description 6
• 210000003630 histaminocyte Anatomy 0.000 description 6
• 208000032839 leukemia Diseases 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 210000000274 microglia Anatomy 0.000 description 6
• 230000001400 myeloablative effect Effects 0.000 description 6
• 229910052760 oxygen Inorganic materials 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 230000002062 proliferating effect Effects 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• 238000003860 storage Methods 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 229910052717 sulfur Inorganic materials 0.000 description 6
• 229920002397 thermoplastic olefin Polymers 0.000 description 6
• 238000001890 transfection Methods 0.000 description 6
• HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 5
• 241000701022 Cytomegalovirus Species 0.000 description 5
• 102000053602 DNA Human genes 0.000 description 5
• 108091029865 Exogenous DNA Proteins 0.000 description 5
• 101710163270 Nuclease Proteins 0.000 description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 5
• 239000012634 fragment Substances 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 125000004474 heteroalkylene group Chemical group 0.000 description 5
• 229940125721 immunosuppressive agent Drugs 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 230000006780 non-homologous end joining Effects 0.000 description 5
• 210000004940 nucleus Anatomy 0.000 description 5
• 229920000768 polyamine Polymers 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000008439 repair process Effects 0.000 description 5
• 239000011593 sulfur Substances 0.000 description 5
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 4
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
• 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 4
• 241000282693 Cercopithecidae Species 0.000 description 4
• 206010010904 Convulsion Diseases 0.000 description 4
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• 208000029462 Immunodeficiency disease Diseases 0.000 description 4
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 4
• 208000003456 Juvenile Arthritis Diseases 0.000 description 4
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 108091093105 Nuclear DNA Proteins 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
• 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 150000001412 amines Chemical group 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000001186 cumulative effect Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 238000004520 electroporation Methods 0.000 description 4
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 150000002367 halogens Chemical group 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 238000001638 lipofection Methods 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 230000001737 promoting effect Effects 0.000 description 4
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
• 150000003254 radicals Chemical class 0.000 description 4
• 210000000603 stem cell niche Anatomy 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 239000013603 viral vector Substances 0.000 description 4
• LKTNEXPODAWWFM-UHFFFAOYSA-N 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide Chemical compound CC1=CC=CC=C1N=NC(C=C1C)=CC=C1NC(=O)C1=CC=NN1C LKTNEXPODAWWFM-UHFFFAOYSA-N 0.000 description 3
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
• 208000032467 Aplastic anaemia Diseases 0.000 description 3
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 3
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
• 206010053138 Congenital aplastic anaemia Diseases 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 229920002527 Glycogen Polymers 0.000 description 3
• 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 3
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
• 206010061598 Immunodeficiency Diseases 0.000 description 3
• 102100022338 Integrin alpha-M Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
• 208000035809 Lymphohistiocytosis Diseases 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
• 206010029260 Neuroblastoma Diseases 0.000 description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
• 208000010346 Sphingolipidoses Diseases 0.000 description 3
• 201000001307 Sphingolipidosis Diseases 0.000 description 3
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
• 238000010459 TALEN Methods 0.000 description 3
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
• 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
• 108010020764 Transposases Proteins 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 125000006193 alkinyl group Chemical group 0.000 description 3
• 125000000732 arylene group Chemical group 0.000 description 3
• 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 125000002619 bicyclic group Chemical group 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 125000002091 cationic group Chemical group 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• 208000019069 chronic childhood arthritis Diseases 0.000 description 3
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
• 229940125782 compound 2 Drugs 0.000 description 3
• 125000002993 cycloalkylene group Chemical group 0.000 description 3
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
• 210000000222 eosinocyte Anatomy 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 229940096919 glycogen Drugs 0.000 description 3
• 125000006588 heterocycloalkylene group Chemical group 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 150000004677 hydrates Chemical class 0.000 description 3
• 230000007813 immunodeficiency Effects 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 230000005291 magnetic effect Effects 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 210000003593 megakaryocyte Anatomy 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000002025 microglial effect Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 208000002865 osteopetrosis Diseases 0.000 description 3
• 150000003904 phospholipids Chemical class 0.000 description 3
• 210000002826 placenta Anatomy 0.000 description 3
• YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 150000003212 purines Chemical class 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 238000006798 ring closing metathesis reaction Methods 0.000 description 3
• 208000007056 sickle cell anemia Diseases 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• FTJHKZQHQDKPFJ-UHFFFAOYSA-N (carbamoylamino)carbamic acid Chemical compound NC(=O)NNC(O)=O FTJHKZQHQDKPFJ-UHFFFAOYSA-N 0.000 description 2
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
• KDDXOGDIPZSCTM-UHFFFAOYSA-N 2-[1H-indol-3-yl(oxo)methyl]-4-thiazolecarboxylic acid methyl ester Chemical compound COC(=O)C1=CSC(C(=O)C=2C3=CC=CC=C3NC=2)=N1 KDDXOGDIPZSCTM-UHFFFAOYSA-N 0.000 description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• 102100033051 40S ribosomal protein S19 Human genes 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 241000701844 Bacillus virus phi29 Species 0.000 description 2
• 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 2
• 208000019838 Blood disease Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 108090000397 Caspase 3 Proteins 0.000 description 2
• 102100029855 Caspase-3 Human genes 0.000 description 2
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
• 230000007018 DNA scission Effects 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 208000001640 Fibromyalgia Diseases 0.000 description 2
• 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
• 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
• 108010075704 HLA-A Antigens Proteins 0.000 description 2
• 108010058607 HLA-B Antigens Proteins 0.000 description 2
• 102000006354 HLA-DR Antigens Human genes 0.000 description 2
• 108010058597 HLA-DR Antigens Proteins 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• 102000026633 IL6 Human genes 0.000 description 2
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
• 101710177504 Kit ligand Proteins 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• 241000713666 Lentivirus Species 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 102000043129 MHC class I family Human genes 0.000 description 2
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical group [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 208000008601 Polycythemia Diseases 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• 108020005091 Replication Origin Proteins 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 208000002903 Thalassemia Diseases 0.000 description 2
• 108091036066 Three prime untranslated region Proteins 0.000 description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• 102000008579 Transposases Human genes 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 206010046865 Vaccinia virus infection Diseases 0.000 description 2
• 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 2
• MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
• 150000001241 acetals Chemical class 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 125000002877 alkyl aryl group Chemical group 0.000 description 2
• 125000005213 alkyl heteroaryl group Chemical group 0.000 description 2
• 125000003275 alpha amino acid group Chemical group 0.000 description 2
• 150000007854 aminals Chemical class 0.000 description 2
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 229940092117 atgam Drugs 0.000 description 2
• 239000007640 basal medium Substances 0.000 description 2
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 238000010322 bone marrow transplantation Methods 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 101150038500 cas9 gene Proteins 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 229960005091 chloramphenicol Drugs 0.000 description 2
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 229910003460 diamond Inorganic materials 0.000 description 2
• 239000010432 diamond Substances 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000003814 drug Substances 0.000 description 2
• 241001493065 dsRNA viruses Species 0.000 description 2
• 230000005684 electric field Effects 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 210000003780 hair follicle Anatomy 0.000 description 2
• 210000000777 hematopoietic system Anatomy 0.000 description 2
• 125000005549 heteroarylene group Chemical group 0.000 description 2
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 229940127121 immunoconjugate Drugs 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 2
• 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 229960000318 kanamycin Drugs 0.000 description 2
• 229930027917 kanamycin Natural products 0.000 description 2
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
• 229930182823 kanamycin A Natural products 0.000 description 2
• 150000003951 lactams Chemical class 0.000 description 2
• 150000002596 lactones Chemical class 0.000 description 2
• HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
• 230000003458 metachromatic effect Effects 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 210000003098 myoblast Anatomy 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 230000030147 nuclear export Effects 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 210000004976 peripheral blood cell Anatomy 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 230000002629 repopulating effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 150000003555 thioacetals Chemical class 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 125000004953 trihalomethyl group Chemical group 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 208000007089 vaccinia Diseases 0.000 description 2
• FOSDRKVGBZLRRC-QMMNWOAZSA-N (1r,2r)-1-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1-n-(5,6,7,8-tetrahydroquinolin-8-yl)cyclopentane-1,2-diamine Chemical compound N[C@@H]1CCC[C@H]1N(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 FOSDRKVGBZLRRC-QMMNWOAZSA-N 0.000 description 1
• UPXZXNQWHQWURB-UXMRNZNESA-N (2S)-2-amino-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydroquinolin-8-yl)butanediamide Chemical compound C1CCC2=CC=CN=C2C1N(C(=O)[C@H](CC(N)=O)N)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 UPXZXNQWHQWURB-UXMRNZNESA-N 0.000 description 1
• RSGZLNITLGQDQL-XGLRFROISA-N (2s)-2-amino-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-(5,6,7,8-tetrahydroquinolin-8-yl)propanamide Chemical compound C1CCC2=CC=CN=C2C1N(C(=O)[C@@H](N)C)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 RSGZLNITLGQDQL-XGLRFROISA-N 0.000 description 1
• JMISKXGBLMKCBE-PMCHYTPCSA-N (2s)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-(5,6,7,8-tetrahydroquinolin-8-yl)pyrrolidine-2-carboxamide Chemical compound C=1C=C(CNCC=2N=CC=CC=2)C=CC=1CN(C1C2=NC=CC=C2CCC1)C(=O)[C@@H]1CCCN1 JMISKXGBLMKCBE-PMCHYTPCSA-N 0.000 description 1
• SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
• HLRWRACNIJFYEO-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotetradecane Chemical compound C1CCNCCNCCNCCNC1 HLRWRACNIJFYEO-UHFFFAOYSA-N 0.000 description 1
• LXUJUJYVZSBOKU-UHFFFAOYSA-N 1,4,7-triazacyclotetradecane Chemical compound C1CCCNCCNCCNCCC1 LXUJUJYVZSBOKU-UHFFFAOYSA-N 0.000 description 1
• VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
• QPFUQMRWZANCBG-UHFFFAOYSA-N 1-[1-(1,4,8,11-tetrazacyclotetradec-1-yl)hexan-2-yl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C1CCNCCNCCCNCCN1C(CCCC)CN1CCCNCCNCCCNCC1 QPFUQMRWZANCBG-UHFFFAOYSA-N 0.000 description 1
• GVPVISVGQUQSSG-UHFFFAOYSA-N 1-[2-(1,4,8,11-tetrazacyclotetradec-1-yl)ethyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C1CCNCCNCCCNCCN1CCN1CCCNCCNCCCNCC1 GVPVISVGQUQSSG-UHFFFAOYSA-N 0.000 description 1
• PMGQWFFOFZQXSJ-UHFFFAOYSA-N 1-[4-(1,7-diazacyclotetradec-4-ylmethyl)phenyl]-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=C(CC2CCNCCCCCCCNCC2)C=CC=1CNCC1=CC=CC=N1 PMGQWFFOFZQXSJ-UHFFFAOYSA-N 0.000 description 1
• GKJYLJLZQLRHLX-UHFFFAOYSA-N 1-[4-[(11,11-difluoro-1,4,7-triazacyclotetradec-4-yl)methyl]phenyl]-n-(pyridin-2-ylmethyl)methanamine Chemical compound C1CNCCCC(F)(F)CCCNCCN1CC(C=C1)=CC=C1CNCC1=CC=CC=N1 GKJYLJLZQLRHLX-UHFFFAOYSA-N 0.000 description 1
• PTDLVNBLFNWNGP-UHFFFAOYSA-N 1-[[2,3,4,6-tetrachloro-5-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound ClC=1C(CN2CCNCCCNCCNCCC2)=C(Cl)C(Cl)=C(Cl)C=1CN1CCCNCCNCCCNCC1 PTDLVNBLFNWNGP-UHFFFAOYSA-N 0.000 description 1
• SEFLKOOVNJZTFY-UHFFFAOYSA-N 1-[[2,3,5,6-tetrafluoro-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound FC=1C(F)=C(CN2CCNCCCNCCNCCC2)C(F)=C(F)C=1CN1CCCNCCNCCCNCC1 SEFLKOOVNJZTFY-UHFFFAOYSA-N 0.000 description 1
• NYQPBUORMFOXKK-UHFFFAOYSA-N 1-[[2,5-dichloro-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound ClC=1C=C(CN2CCNCCCNCCNCCC2)C(Cl)=CC=1CN1CCCNCCNCCCNCC1 NYQPBUORMFOXKK-UHFFFAOYSA-N 0.000 description 1
• GBUVEYKYEYRGEU-UHFFFAOYSA-N 1-[[2,5-dimethyl-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound CC=1C=C(CN2CCNCCCNCCNCCC2)C(C)=CC=1CN1CCCNCCNCCCNCC1 GBUVEYKYEYRGEU-UHFFFAOYSA-N 0.000 description 1
• CGBPRRHXVCXIKY-UHFFFAOYSA-N 1-[[2-bromo-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C(Br)=CC=1CN1CCCNCCNCCCNCC1 CGBPRRHXVCXIKY-UHFFFAOYSA-N 0.000 description 1
• PXTXSIAYIFRMDE-UHFFFAOYSA-N 1-[[3-(1,4,7,10-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,7,10-tetrazacyclotetradecane Chemical compound C=1C=CC(CN2CCNCCNCCNCCCC2)=CC=1CN1CCCCNCCNCCNCC1 PXTXSIAYIFRMDE-UHFFFAOYSA-N 0.000 description 1
• TWROELGOZKDRSL-UHFFFAOYSA-N 1-[[3-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=CC(CN2CCNCCCNCCNCCC2)=CC=1CN1CCCNCCNCCCNCC1 TWROELGOZKDRSL-UHFFFAOYSA-N 0.000 description 1
• UPPOFVSOKBVXDP-UHFFFAOYSA-N 1-[[3-(1,5,9-triazacyclododec-1-ylmethyl)phenyl]methyl]-1,5,9-triazacyclododecane Chemical compound C=1C=CC(CN2CCCNCCCNCCC2)=CC=1CN1CCCNCCCNCCC1 UPPOFVSOKBVXDP-UHFFFAOYSA-N 0.000 description 1
• PEVCHIZAJILPKB-UHFFFAOYSA-N 1-[[3-nitro-5-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C(CN2CCNCCCNCCNCCC2)=CC([N+](=O)[O-])=CC=1CN1CCCNCCNCCCNCC1 PEVCHIZAJILPKB-UHFFFAOYSA-N 0.000 description 1
• BNXRQMCWXHZHTF-UHFFFAOYSA-N 1-[[4-(1,4,7,10-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,7,10-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCNCCNCCNCCCC2)C=CC=1CN1CCCCNCCNCCNCC1 BNXRQMCWXHZHTF-UHFFFAOYSA-N 0.000 description 1
• QNIZOKGSHPITQD-UHFFFAOYSA-N 1-[[4-(1,4,7,11-tetrazacyclotetradec-11-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCNCCC1 QNIZOKGSHPITQD-UHFFFAOYSA-N 0.000 description 1
• BKJDPXSXCZMISN-UHFFFAOYSA-N 1-[[6-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)pyridin-2-yl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=CC(CN2CCNCCCNCCNCCC2)=NC=1CN1CCCNCCNCCCNCC1 BKJDPXSXCZMISN-UHFFFAOYSA-N 0.000 description 1
• BJXXQCURPZWADT-UHFFFAOYSA-N 1-methyl-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1CC2=CC=CC=C2C(C)C1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 BJXXQCURPZWADT-UHFFFAOYSA-N 0.000 description 1
• YRMKTQNDPSHONR-UHFFFAOYSA-N 1-phenyl-n-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]methanamine Chemical compound C=1C=CC=CC=1CNCC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 YRMKTQNDPSHONR-UHFFFAOYSA-N 0.000 description 1
• IAGWLDWQRRSAIK-UHFFFAOYSA-N 11-[[4-(1,4,7,11-tetrazacyclotetradec-11-ylmethyl)phenyl]methyl]-1,4,7,11-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCCNCCNCCNCCC2)C=CC=1CN1CCCNCCNCCNCCC1 IAGWLDWQRRSAIK-UHFFFAOYSA-N 0.000 description 1
• JUUZQMUWOVDZSD-UHFFFAOYSA-N 1h-imidazole;pyrazine Chemical compound C1=CNC=N1.C1=CN=CC=N1 JUUZQMUWOVDZSD-UHFFFAOYSA-N 0.000 description 1
• SBPIDKODQVLBGV-UHFFFAOYSA-N 1h-imidazole;pyridine Chemical compound C1=CNC=N1.C1=CC=NC=C1 SBPIDKODQVLBGV-UHFFFAOYSA-N 0.000 description 1
• MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
• VTSJNUHXDBTHAG-UHFFFAOYSA-N 2-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl-(5,6,7,8-tetrahydroquinolin-8-yl)amino]acetic acid Chemical compound C1CCC2=CC=CN=C2C1N(CC(=O)O)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VTSJNUHXDBTHAG-UHFFFAOYSA-N 0.000 description 1
• UQJUPEBNPXJTGH-UHFFFAOYSA-N 2-[[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methylamino]methyl]aniline Chemical compound NC1=CC=CC=C1CNCC(C=C1)=CC=C1CN1CCNCCCNCCNCCC1 UQJUPEBNPXJTGH-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• VRRHGRADXKUDHV-UHFFFAOYSA-N 2-amino-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-(5,6,7,8-tetrahydroquinolin-8-yl)acetamide Chemical compound C1CCC2=CC=CN=C2C1N(C(=O)CN)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VRRHGRADXKUDHV-UHFFFAOYSA-N 0.000 description 1
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
• NOWAALMFKTVKNA-UHFFFAOYSA-N 2-phenyl-n-(pyridin-2-ylmethyl)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2N=CC=CC=2)C2C3=NC(=CC=C3CCC2)C=2C=CC=CC=2)C=CC=1CNCC1=CC=CC=N1 NOWAALMFKTVKNA-UHFFFAOYSA-N 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
• SELQQIVKCRNKIT-UHFFFAOYSA-N 3-benzyl-1-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1-(5,6,7,8-tetrahydroquinolin-8-yl)urea Chemical compound C=1C=C(CNCC=2N=CC=CC=2)C=CC=1CN(C1C2=NC=CC=C2CCC1)C(=O)NCC1=CC=CC=C1 SELQQIVKCRNKIT-UHFFFAOYSA-N 0.000 description 1
• WVAWOUKVAOMCPU-UHFFFAOYSA-N 3-phenyl-1-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1-(5,6,7,8-tetrahydroquinolin-8-yl)urea Chemical compound C=1C=C(CNCC=2N=CC=CC=2)C=CC=1CN(C1C2=NC=CC=C2CCC1)C(=O)NC1=CC=CC=C1 WVAWOUKVAOMCPU-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• CSUSIKFJDHUQEQ-UHFFFAOYSA-N 6-methoxy-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1CC2=CC(OC)=CC=C2CC1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 CSUSIKFJDHUQEQ-UHFFFAOYSA-N 0.000 description 1
• DKDLSEPIAWSONV-UHFFFAOYSA-N 7-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methylamino]-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1C=2C(O)=CC=CC=2CCC1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 DKDLSEPIAWSONV-UHFFFAOYSA-N 0.000 description 1
• HRXBVPDNMXEMSA-UHFFFAOYSA-N 7-methoxy-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1C2=CC(OC)=CC=C2CCC1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 HRXBVPDNMXEMSA-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• XUQNFXXFHDZHNO-UHFFFAOYSA-N 8-fluoro-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1C=2C(F)=CC=CC=2CCC1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 XUQNFXXFHDZHNO-UHFFFAOYSA-N 0.000 description 1
• 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
• 102000055025 Adenosine deaminases Human genes 0.000 description 1
• 208000008190 Agammaglobulinemia Diseases 0.000 description 1
• 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
• 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 241000714266 Bovine leukemia virus Species 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
• 108091092236 Chimeric RNA Proteins 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 241000251730 Chondrichthyes Species 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• 108020004638 Circular DNA Proteins 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
• 208000013558 Developmental Bone disease Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 208000010772 Dog disease Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
• 201000004939 Fanconi anemia Diseases 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
• 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 206010061979 Genital pain Diseases 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
• 108010052199 HLA-C Antigens Proteins 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
• 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• 241000282620 Hylobates sp. Species 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 208000027601 Inner ear disease Diseases 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 102100020880 Kit ligand Human genes 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
• 201000005505 Measles Diseases 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 208000021908 Myocardial disease Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 241000714209 Norwalk virus Species 0.000 description 1
• 240000007019 Oxalis corniculata Species 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
• 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 241000709664 Picornaviridae Species 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 108010034634 Repressor Proteins Proteins 0.000 description 1
• 102000009661 Repressor Proteins Human genes 0.000 description 1
• 241000712907 Retroviridae Species 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 241001468001 Salmonella virus SP6 Species 0.000 description 1
• 241000287219 Serinus canaria Species 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 206010072610 Skeletal dysplasia Diseases 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 241000713675 Spumavirus Species 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• 108091028113 Trans-activating crRNA Proteins 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
• NRAUADCLPJTGSF-ZPGVOIKOSA-N [(2r,3s,4r,5r,6r)-6-[[(3as,7r,7as)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3s)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@@H](O)[C@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-ZPGVOIKOSA-N 0.000 description 1
• ZOTXACXDJNHROX-UHFFFAOYSA-N [Zn].[Zn].C1(=CC=C(C=C1)CN1CCNCCCNCCNCCC1)CN1CCNCCCNCCNCCC1 Chemical compound [Zn].[Zn].C1(=CC=C(C=C1)CN1CCNCCCNCCNCCC1)CN1CCNCCCNCCNCCC1 ZOTXACXDJNHROX-UHFFFAOYSA-N 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 210000004504 adult stem cell Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 239000002295 alkylating antineoplastic agent Substances 0.000 description 1
• IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 210000004381 amniotic fluid Anatomy 0.000 description 1
• 230000000781 anti-lymphocytic effect Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 238000002617 apheresis Methods 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• JAPMJSVZDUYFKL-UHFFFAOYSA-N bicyclo[3.1.0]hexane Chemical compound C1CCC2CC21 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 239000012503 blood component Substances 0.000 description 1
• 238000009583 bone marrow aspiration Methods 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 210000000069 breast epithelial cell Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000005569 butenylene group Chemical group 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 230000006041 cell recruitment Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 210000004252 chorionic villi Anatomy 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 230000001332 colony forming effect Effects 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 230000037011 constitutive activity Effects 0.000 description 1
• 201000003278 cryoglobulinemia Diseases 0.000 description 1
• 238000005138 cryopreservation Methods 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004976 cyclobutylene group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• JJWIOXUMXIOXQN-UHFFFAOYSA-N cyclohexadecane Chemical compound C1CCCCCCCCCCCCCCC1 JJWIOXUMXIOXQN-UHFFFAOYSA-N 0.000 description 1
• 125000004956 cyclohexylene group Chemical group 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004979 cyclopentylene group Chemical group 0.000 description 1
• 125000004980 cyclopropylene group Chemical group 0.000 description 1
• 239000000409 cytokine receptor agonist Substances 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000008260 defense mechanism Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 239000000412 dendrimer Substances 0.000 description 1
• 229920000736 dendritic polymer Polymers 0.000 description 1
• 210000005258 dental pulp stem cell Anatomy 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 229960003722 doxycycline Drugs 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000005670 electromagnetic radiation Effects 0.000 description 1
• 230000009881 electrostatic interaction Effects 0.000 description 1
• 238000005421 electrostatic potential Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 210000002514 epidermal stem cell Anatomy 0.000 description 1
• 238000006345 epimerization reaction Methods 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
• 229950010333 exalamide Drugs 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 210000000604 fetal stem cell Anatomy 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 108091008053 gene clusters Proteins 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 102000018146 globin Human genes 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 150000002373 hemiacetals Chemical class 0.000 description 1
• 210000003897 hepatic stem cell Anatomy 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 125000004475 heteroaralkyl group Chemical group 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 208000033065 inborn errors of immunity Diseases 0.000 description 1
• 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000004966 intestinal stem cell Anatomy 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 125000005990 isobenzothienyl group Chemical group 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 229940062717 keppra Drugs 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 208000002741 leukoplakia Diseases 0.000 description 1
• 229960004002 levetiracetam Drugs 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 201000003265 lymphadenitis Diseases 0.000 description 1
• 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 239000006148 magnetic separator Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229960004635 mesna Drugs 0.000 description 1
• 229940101533 mesnex Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
• 108091070501 miRNA Proteins 0.000 description 1
• 239000002679 microRNA Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• JJVZSYKFCOBILL-MKMRYRNGSA-N motixafortide Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)c1ccc(F)cc1 JJVZSYKFCOBILL-MKMRYRNGSA-N 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 230000036473 myasthenia Effects 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• YORNHNMWEWVKTM-UHFFFAOYSA-N n'-(1-methyl-3,4-dihydro-2h-quinolin-8-yl)-n-(pyridin-2-ylmethyl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]ethane-1,2-diamine Chemical compound C=12N(C)CCCC2=CC=CC=1N(CC=1C=CC(CNCC=2N=CC=CC=2)=CC=1)CCNCC1=CC=CC=N1 YORNHNMWEWVKTM-UHFFFAOYSA-N 0.000 description 1
• OBCGVCHGTISUSB-UHFFFAOYSA-N n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C1CCC2=CC=CN=C2C1N(CCN)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 OBCGVCHGTISUSB-UHFFFAOYSA-N 0.000 description 1
• TWAJZSBBOJFYRN-UHFFFAOYSA-N n,n-bis[(2-methoxyphenyl)methyl]-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound COC1=CC=CC=C1CN(CC=1C(=CC=CC=1)OC)CCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 TWAJZSBBOJFYRN-UHFFFAOYSA-N 0.000 description 1
• CVCOZIAFFAJQFJ-UHFFFAOYSA-N n-(1h-imidazol-2-ylmethyl)-n'-(1-methyl-3,4-dihydro-2h-quinolin-8-yl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]ethane-1,2-diamine Chemical compound C=12N(C)CCCC2=CC=CC=1N(CC=1C=CC(CNCC=2N=CC=CC=2)=CC=1)CCNCC1=NC=CN1 CVCOZIAFFAJQFJ-UHFFFAOYSA-N 0.000 description 1
• JNSXPMQONUZISJ-UHFFFAOYSA-N n-(1h-imidazol-2-ylmethyl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(1,2,3,4-tetrahydronaphthalen-1-yl)ethane-1,2-diamine Chemical compound N=1C=CNC=1CNCCN(C1C2=CC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 JNSXPMQONUZISJ-UHFFFAOYSA-N 0.000 description 1
• WEZLIYLAGMXZGO-UHFFFAOYSA-N n-(1h-imidazol-2-ylmethyl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound N=1C=CNC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 WEZLIYLAGMXZGO-UHFFFAOYSA-N 0.000 description 1
• CFZVQPIGMZCPFB-UHFFFAOYSA-N n-(1h-imidazol-2-ylmethyl)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-7-amine Chemical compound C=1C=C(CN(CC=2NC=CN=2)C2CC3=NC=CC=C3CC2)C=CC=1CNCC1=CC=CC=N1 CFZVQPIGMZCPFB-UHFFFAOYSA-N 0.000 description 1
• HUQUYFJWQMETSC-UHFFFAOYSA-N n-(1h-imidazol-5-ylmethyl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C=1NC=NC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 HUQUYFJWQMETSC-UHFFFAOYSA-N 0.000 description 1
• GVCLHOJGDIBACL-UHFFFAOYSA-N n-(2-methylpropyl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C1CCC2=CC=CN=C2C1N(CCNCC(C)C)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 GVCLHOJGDIBACL-UHFFFAOYSA-N 0.000 description 1
• MXYQOQASCBNUDZ-UHFFFAOYSA-N n-(2-pyridin-2-ylethyl)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CNCC=2N=CC=CC=2)C=CC=1CN(C1C2=NC=CC=C2CCC1)CCC1=CC=CC=N1 MXYQOQASCBNUDZ-UHFFFAOYSA-N 0.000 description 1
• VFVPTCKHUQJLLP-UHFFFAOYSA-N n-(3-phenylpropyl)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=CC=CC=1CCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VFVPTCKHUQJLLP-UHFFFAOYSA-N 0.000 description 1
• LHDIGVATAPZAFK-UHFFFAOYSA-N n-(3h-imidazo[4,5-c]pyridin-2-ylmethyl)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2NC3=CC=NC=C3N=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 LHDIGVATAPZAFK-UHFFFAOYSA-N 0.000 description 1
• IIBURQNHZQCMKA-UHFFFAOYSA-N n-(furan-2-ylmethyl)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2OC=CC=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 IIBURQNHZQCMKA-UHFFFAOYSA-N 0.000 description 1
• IAKOZGHZGQFGTL-UHFFFAOYSA-N n-(naphthalen-2-ylmethyl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C=1C=C2C=CC=CC2=CC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 IAKOZGHZGQFGTL-UHFFFAOYSA-N 0.000 description 1
• VXQJFGISVRSRNN-UHFFFAOYSA-N n-(naphthalen-2-ylmethyl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)propane-1,3-diamine Chemical compound C=1C=C2C=CC=CC2=CC=1CNCCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VXQJFGISVRSRNN-UHFFFAOYSA-N 0.000 description 1
• DTLFISKHFHZEGV-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C=1C=CC=NC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 DTLFISKHFHZEGV-UHFFFAOYSA-N 0.000 description 1
• UUAATDVFOQOPPY-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C=1C=C(CN(CC=2N=CC=CC=2)C2C3=CC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 UUAATDVFOQOPPY-UHFFFAOYSA-N 0.000 description 1
• WBIDRLRQDSWWJR-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2N=CC=CC=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 WBIDRLRQDSWWJR-UHFFFAOYSA-N 0.000 description 1
• TWTLJZJKDUYSON-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CN=C1 TWTLJZJKDUYSON-UHFFFAOYSA-N 0.000 description 1
• RTHCDPLDSUOFCC-UHFFFAOYSA-N n-(pyridin-4-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=NC=CC=1CNCC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 RTHCDPLDSUOFCC-UHFFFAOYSA-N 0.000 description 1
• HVYYCEMREPWDCX-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C=1C=C(CNC2C3=CC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 HVYYCEMREPWDCX-UHFFFAOYSA-N 0.000 description 1
• UMQKDDXFDPRWKQ-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CNC=2C=3NCCCC=3C=CC=2)C=CC=1CNCC1=CC=CC=N1 UMQKDDXFDPRWKQ-UHFFFAOYSA-N 0.000 description 1
• BOSHJQMZFHOIEM-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-5-amine Chemical compound C=1C=C(CNC2C3=CC=CN=C3CCC2)C=CC=1CNCC1=CC=CC=N1 BOSHJQMZFHOIEM-UHFFFAOYSA-N 0.000 description 1
• OWQFWPLLANSQQV-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-7-amine Chemical compound C=1C=C(CNC2CC3=NC=CC=C3CC2)C=CC=1CNCC1=CC=CC=N1 OWQFWPLLANSQQV-UHFFFAOYSA-N 0.000 description 1
• NVQPVMGRKSAJCF-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CNC2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 NVQPVMGRKSAJCF-UHFFFAOYSA-N 0.000 description 1
• GSCRMXPAVFDDAJ-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-6,7-dihydro-5h-cyclopenta[b]pyridin-7-amine Chemical compound C=1C=C(CNC2C3=NC=CC=C3CC2)C=CC=1CNCC1=CC=CC=N1 GSCRMXPAVFDDAJ-UHFFFAOYSA-N 0.000 description 1
• MQVBXWKLLOZAJE-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-(1,3-thiazol-2-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2SC=CN=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 MQVBXWKLLOZAJE-UHFFFAOYSA-N 0.000 description 1
• RKEIPHNVBYPWQO-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-(5,6,7,8-tetrahydroquinolin-8-yl)-1,3-benzoxazol-2-amine Chemical compound C=1C=C(CN(C2C3=NC=CC=C3CCC2)C=2OC3=CC=CC=C3N=2)C=CC=1CNCC1=CC=CC=N1 RKEIPHNVBYPWQO-UHFFFAOYSA-N 0.000 description 1
• UWAKJWARIZWAPY-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-(5,6,7,8-tetrahydroquinolin-8-yl)pyrazine-2-carboxamide Chemical compound C=1N=CC=NC=1C(=O)N(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 UWAKJWARIZWAPY-UHFFFAOYSA-N 0.000 description 1
• KNFODAPPVSMDKV-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-(5,6,7,8-tetrahydroquinolin-8-yl)pyridine-2-carboxamide Chemical compound C=1C=CC=NC=1C(=O)N(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 KNFODAPPVSMDKV-UHFFFAOYSA-N 0.000 description 1
• SUXWTBAOYVYILW-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-(thiophen-2-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2SC=CC=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 SUXWTBAOYVYILW-UHFFFAOYSA-N 0.000 description 1
• IKZCJMKAYGBAGH-AVJYQCBHSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n-[[(2r)-pyrrolidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(C[C@@H]2NCCC2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 IKZCJMKAYGBAGH-AVJYQCBHSA-N 0.000 description 1
• VKBJDOBPGVLLTB-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]naphthalen-1-amine Chemical compound C=1C=C(CNC=2C3=CC=CC=C3C=CC=2)C=CC=1CNCC1=CC=CC=N1 VKBJDOBPGVLLTB-UHFFFAOYSA-N 0.000 description 1
• DIRVCOZGHSWRJP-UHFFFAOYSA-N n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]quinolin-8-amine Chemical compound C=1C=C(CNC=2C3=NC=CC=C3C=CC=2)C=CC=1CNCC1=CC=CC=N1 DIRVCOZGHSWRJP-UHFFFAOYSA-N 0.000 description 1
• WTTKTVHBIVMMDP-UHFFFAOYSA-N n-[[4-[[(5-phenyl-1h-imidazol-2-yl)methyl-(pyridin-2-ylmethyl)amino]methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1NCC(C=C1)=CC=C1CN(CC=1N=CC=CC=1)CC(NC=1)=NC=1C1=CC=CC=C1 WTTKTVHBIVMMDP-UHFFFAOYSA-N 0.000 description 1
• VPHPNWIYBHWZEE-UHFFFAOYSA-N n-benzyl-n'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-n'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C=1C=CC=CC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VPHPNWIYBHWZEE-UHFFFAOYSA-N 0.000 description 1
• NJDVDIVVFUXOHL-UHFFFAOYSA-N n-benzyl-n-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2C=CC=CC=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 NJDVDIVVFUXOHL-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 229960002715 nicotine Drugs 0.000 description 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 229960002169 plerixafor Drugs 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000006410 propenylene group Chemical group 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 206010039722 scoliosis Diseases 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 239000002924 silencing RNA Substances 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 238000005556 structure-activity relationship Methods 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• 125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 150000007970 thio esters Chemical class 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 230000001256 tonic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 210000003954 umbilical cord Anatomy 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 210000002444 unipotent stem cell Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000017613 viral reproduction Effects 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1